Download PDF
Fortschr Neurol Psychiatr 2016; 84(05): 281-288
DOI: 10.1055/s-0042-106388
Übersicht
© Georg Thieme Verlag KG Stuttgart · New York

Therapie von Antikörper-vermittelten Autoimmunenzephalitiden

Therapy of Antibody-Associated Autoimmune Encephalitis
M. Malter
,
G. R. Fink
Further Information

Publication History

Publication Date:
14 June 2016 (online)

    Permissions and Reprints

Zusammenfassung

Die Entdeckung von Antikörper-vermittelten Autoimmunenzephalitiden als Ursache eines Symptomkomplexes aus epileptischen Anfällen und neuropsychiatrischen Auffälligkeiten und deren gute Prognose unter Immuntherapien ist eine der herausragenden Erfolgsgeschichten der Neurologie der letzten Jahre. In diesem Artikel werden die aktuellen Therapieregime bei Antikörper-vermittelten Autoimmunenzephalitiden erläutert und die individuellen Therapien und Prognosen der bekannten Antikörper-vermittelten Unterformen erläutert. Die wichtigsten therapeutischen Instrumente sind die Tumortherapie, sofern ein Primarius gesichert wird, und Immuntherapien, wobei die Empfehlungen vorwiegend auf retrospektiven Datenanalysen beruhen. Primäres Therapieziel ist die vollständige Remission. Dieses Ziel ist bei den einzelnen Unterformen mit einer unterschiedlichen Wahrscheinlichkeit zu erreichen.

Abstract

The identification of an antibody-associated autoimmune encephalitis underlying diverse syndromes, typically comprising epileptic seizures and neuropsychiatric symptoms, and their favorable prognosis, when treated with immunotherapies, is one of the success stories in neurology in recent years. Here we review current widely used therapy regimens in antibody-associated autoimmune encephalitis and the prognosis of the different antibody-associated sub-forms. The main therapeutic instruments encompass tumor therapy (if tumor is detected) and immunotherapies, though recommendations are mainly based on retrospective data analysis. The primary therapeutic goal is complete remission. The degree to which this can be accomplished depends upon the different sub-forms.

Schlüsselwörter

Autoimmune Enzephalitis - LGI1 - GAD - NMDAR

Key words

autoimmune encephalitis - LGI1 - GAD - NMDAR
 

  • Literatur

  • 1 Irani SR, Gelfand JM, Al-Diwani A et al. Cell-surface central nervous system autoantibodies: clinical relevance and emerging paradigms. Ann Neurol 2014; 76: 168-184
    CrossrefPubMedGoogle Scholar
  • 2 Dalmau J, Tuzun E, Wu HY et al. Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol 2007; 61: 25-36
    Google Scholar
  • 3 Titulaer MJ, McCracken L, Gabilondo I et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol 2013; 12: 157-165
    CrossrefPubMedGoogle Scholar
  • 4 Irani SR, Stagg CJ, Schott JM et al. Faciobrachial dystonic seizures: the influence of immunotherapy on seizure control and prevention of cognitive impairment in a broadening phenotype. Brain 2013; 136: 3151-3162
    CrossrefPubMedGoogle Scholar
  • 5 Hughes RA, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain-Barre syndrome. Cochrane Database Syst Rev 2014; 9: CD002063
    PubMedGoogle Scholar
  • 6 Dalakas MC. The role of IVIg in the treatment of patients with stiff person syndrome and other neurological diseases associated with anti-GAD antibodies. J Neurol 2005; 252 (Suppl. 01) I19-l25
    CrossrefPubMedGoogle Scholar
  • 7 Schroder A, Linker RA, Gold R. Plasmapheresis for neurological disorders. Expert Rev Neurother 2009; 9: 1331-1339
    CrossrefPubMedGoogle Scholar
  • 8 Krishnan C, Kaplin AI, Brodsky RA et al. Reduction of disease activity and disability with high-dose cyclophosphamide in patients with aggressive multiple sclerosis. Arch Neurol 2008; 65: 1044-1051
    CrossrefPubMedGoogle Scholar
  • 9 Kosmidis ML, Dalakas MC. Practical considerations on the use of rituximab in autoimmune neurological disorders. Ther Adv Neurol Disord 2010; 3: 93-105
    CrossrefPubMedGoogle Scholar
  • 10 Petereit HF, Rubbert-Roth A. Rituximab levels in cerebrospinal fluid of patients with neurological autoimmune disorders. Mult Scler 2009; 15: 189-192
    PubMedGoogle Scholar
  • 11 Malter MP, Frisch C, Zeitler H et al. Treatment of immune-mediated temporal lobe epilepsy with GAD antibodies. Seizure 2015; 30: 57-63
    CrossrefPubMedGoogle Scholar
  • 12 Widman G, Golombeck K, Hautzel H et al. Treating a GAD65 Antibody-Associated Limbic Encephalitis with Basiliximab: A Case Study. Front Neurol 2015; 6: 167
    PubMedGoogle Scholar
  • 13 Clifford DB, Ances B, Costello C et al. Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis. Arch Neurol 2011; 68: 1156-1164
    CrossrefPubMedGoogle Scholar
  • 14 Keime-Guibert F, Graus F, Fleury A et al. Treatment of paraneoplastic neurological syndromes with antineuronal antibodies (Anti-Hu, anti-Yo) with a combination of immunoglobulins, cyclophosphamide, and methylprednisolone. J Neurol Neurosurg Psychiatry 2000; 68: 479-482
    CrossrefPubMedGoogle Scholar
  • 15 Almeida V, Pimentel J, Campos A et al. Surgical control of limbic encephalitis associated with LGI1 antibodies. Epileptic Disord 2012; 14: 345-348
    PubMedGoogle Scholar
  • 16 Weimer T, Boling W, Pryputniewicz D et al. Temporal lobectomy for refractory status epilepticus in a case of limbic encephalitis. J Neurosurg 2008; 109: 742-745
    CrossrefPubMedGoogle Scholar
  • 17 Muehlebner A, Groeppel G, Pahs G et al. Beneficial effect of epilepsy surgery in a case of childhood non-paraneoplastic limbic encephalitis. Epilepsy Res 2010; 90: 295-299
    CrossrefPubMedGoogle Scholar
  • 18 Malter MP, Frisch C, Schoene-Bake JC et al. Outcome of limbic encephalitis with VGKC-complex antibodies: relation to antigenic specificity. J Neurol 2014; 261: 1695-1705
    PubMedGoogle Scholar
  • 19 Mathern GW, Babb TL, Vickrey BG et al. The clinical-pathogenic mechanisms of hippocampal neuron loss and surgical outcomes in temporal lobe epilepsy. Brain 1995; 118 (01) 105-118
    CrossrefPubMedGoogle Scholar
  • 20 Dalmau J, Gleichman AJ, Hughes EG et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol 2008; 7: 1091-1098
    CrossrefPubMedGoogle Scholar
  • 21 Dalmau J, Lancaster E, Martinez-Hernandez E et al. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol 2011; 10: 63-74
    Google Scholar
  • 22 Tanyi JL, Marsh EB, Dalmau J et al. Reversible paraneoplastic encephalitis in three patients with ovarian neoplasms. Acta Obstet Gynecol Scand 2012; 91: 630-634
    CrossrefPubMedGoogle Scholar
  • 23 Boeck AL, Logemann F, Krauss T et al. Ovarectomy despite Negative Imaging in Anti-NMDA Receptor Encephalitis: Effective Even Late. Case Rep Neurol Med 2013; 2013: 843192
    PubMedGoogle Scholar
  • 24 Tatencloux S, Chretien P, Rogemond V et al. Intrathecal treatment of anti-N-Methyl-D-aspartate receptor encephalitis in children. Dev Med Child Neurol 2015; 57: 95-99
    PubMedGoogle Scholar
  • 25 Liba Z, Sebronova V, Komarek V et al. Prevalence and treatment of anti-NMDA receptor encephalitis. Lancet Neurol 2013; 12: 424-425
    CrossrefPubMedGoogle Scholar
  • 26 Zekeridou A, Karantoni E, Viaccoz A et al. Treatment and outcome of children and adolescents with N-methyl-D-aspartate receptor encephalitis. J Neurol 2015; 262: 1859-1866
    CrossrefPubMedGoogle Scholar
  • 27 Dale RC, Brilot F, Duffy LV et al. Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease. Neurology 2014; 83: 142-150
    CrossrefPubMedGoogle Scholar
  • 28 Byrne S, Walsh C, Hacohen Y et al. Earlier treatment of NMDAR antibody encephalitis in children results in a better outcome. Neurol Neuroimmunol Neuroinflamm 2015; 2: e130
    PubMedGoogle Scholar
  • 29 Gabilondo I, Saiz A, Galan L et al. Analysis of relapses in anti-NMDAR encephalitis. Neurology 2011; 77: 996-999
    CrossrefPubMedGoogle Scholar
  • 30 Irani SR, Alexander S, Waters P et al. Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan's syndrome and acquired neuromyotonia. Brain 2010; 133: 2734-2748
    CrossrefPubMedGoogle Scholar
  • 31 Lai M, Huijbers MG, Lancaster E et al. Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case series. Lancet Neurol 2010; 9: 776-785
    CrossrefPubMedGoogle Scholar
  • 32 Bien CG, Vincent A, Barnett MH et al. Immunopathology of autoantibody-associated encephalitides: clues for pathogenesis. Brain 2012; 135: 1622-1638
    CrossrefPubMedGoogle Scholar
  • 33 Nosadini M, Mohammad SS, Ramanathan S et al. Immune therapy in autoimmune encephalitis: a systematic review. Expert Rev Neurother 2015; 15: 1391-1419
    CrossrefPubMedGoogle Scholar
  • 34 Irani SR, Michell AW, Lang B et al. Faciobrachial dystonic seizures precede Lgi1 antibody limbic encephalitis. Ann Neurol 2011; 69: 892-900
    CrossrefPubMedGoogle Scholar
  • 35 Bettcher BM, Gelfand JM, Irani SR et al. More than memory impairment in voltage-gated potassium channel complex encephalopathy. Eur J Neurol 2014; 21: 1301-1310
    CrossrefPubMedGoogle Scholar
  • 36 Vincent A. Stiff, twitchy or wobbly: are GAD antibodies pathogenic?. Brain 2008; 131: 2536-2537
    CrossrefPubMedGoogle Scholar
  • 37 Dubey D, Samudra N, Gupta P et al. Retrospective case series of the clinical features, management and outcomes of patients with autoimmune epilepsy. Seizure 2015; 29: 143-147
    CrossrefPubMedGoogle Scholar
  • 38 Khawaja AM, DeWolfe JL, Miller DW et al. New-onset refractory status epilepticus (NORSE)--The potential role for immunotherapy. Epilepsy Behav 2015; 47: 17-23
    CrossrefPubMedGoogle Scholar
  • 39 Lilleker JB, Biswas V, Mohanraj R. Glutamic acid decarboxylase (GAD) antibodies in epilepsy: diagnostic yield and therapeutic implications. Seizure 2014; 23: 598-602
    CrossrefPubMedGoogle Scholar
  • 40 Falip M, Carreno M, Miro J et al. Prevalence and immunological spectrum of temporal lobe epilepsy with glutamic acid decarboxylase antibodies. Eur J Neurol 2012; 19: 827-833
    PubMedGoogle Scholar
  • 41 Farooqi MS, Lai Y, Lancaster E et al. Therapeutic plasma exchange and immunosuppressive therapy in a patient with anti-GAD antibody-related epilepsy: quantification of the antibody response. J Clin Apher 2015; 30: 8-14
    CrossrefPubMedGoogle Scholar
  • 42 Georgieva Z, Parton M. Cerebellar ataxia and epilepsy with anti-GAD antibodies: treatment with IVIG and plasmapheresis. BMJ Case Rep 2014; DOI: 10.1136/bcr-2013-202314.
    PubMedGoogle Scholar
  • 43 Suleiman J, Wright S, Gill D et al. Autoantibodies to neuronal antigens in children with new-onset seizures classified according to the revised ILAE organization of seizures and epilepsies. Epilepsia 2013; 54: 2091-2100
    CrossrefPubMedGoogle Scholar
  • 44 Akman CI, Patterson MC, Rubinstein A et al. Limbic encephalitis associated with anti-GAD antibody and common variable immune deficiency. Dev Med Child Neurol 2009; 51: 563-567
    CrossrefPubMedGoogle Scholar
  • 45 Mazzi G, Roia DD, Cruciatti B et al. Plasma exchange for anti GAD associated non paraneoplastic limbic encephalitis. Transfus Apher Sci 2008; 39: 229-233
    CrossrefPubMedGoogle Scholar
  • 46 Kanter IC, Huttner HB, Staykov D et al. Cyclophosphamide for anti-GAD antibody-positive refractory status epilepticus. Epilepsia 2008; 49: 914-920
    CrossrefPubMedGoogle Scholar
  • 47 Vulliemoz S, Vanini G, Truffert A et al. Epilepsy and cerebellar ataxia associated with anti-glutamic acid decarboxylase antibodies. J Neurol Neurosurg Psychiatry 2007; 78: 187-189
    CrossrefPubMedGoogle Scholar
  • 48 Yoshimoto T, Doi M, Fukai N et al. Type 1 diabetes mellitus and drug-resistant epilepsy: presence of high titer of anti-glutamic acid decarboxylase autoantibodies in serum and cerebrospinal fluid. Intern Med 2005; 44: 1174-1177
    CrossrefPubMedGoogle Scholar
  • 49 Nociti V, Frisullo G, Tartaglione T et al. Refractory generalized seizures and cerebellar ataxia associated with anti-GAD antibodies responsive to immunosuppressive treatment. Eur J Neurol 2010; 17: e5
    CrossrefPubMedGoogle Scholar
  • 50 Markakis I, Alexopoulos H, Poulopoulou C et al. Immunotherapy-responsive limbic encephalitis with antibodies to glutamic acid decarboxylase. J Neurol Sci 2014; 343: 192-194
    CrossrefPubMedGoogle Scholar
  • 51 Kohler W, Ehrlich S, Dohmen C et al. Tryptophan immunoadsorption for the treatment of autoimmune encephalitis. Eur J Neurol 2015; 22: 203-206
    CrossrefPubMedGoogle Scholar
  • 52 Garcia ME, Morales IG, Fernandez JM et al. Episodes of loss of consciousness in a patient with a background of cerebral venous thrombosis. Epileptic Disord 2013; 15: 175-180
    PubMedGoogle Scholar
  • 53 Mishra N, Rodan LH, Nita DA et al. Anti-glutamic Acid decarboxylase antibody associated limbic encephalitis in a child: expanding the spectrum of pediatric inflammatory brain diseases. J Child Neurol 2014; 29: 677-683
    CrossrefPubMedGoogle Scholar
  • 54 Sharma A, Dubey D, Sawhney A et al. GAD65 Positive Autoimmune Limbic Encephalitis: A Case Report and Review of Literature. J Clin Med Res 2012; 4: 424-428
    PubMedGoogle Scholar
  • 55 Finelli PF. Autoimmune Limbic Encephalitis With GAD Antibodies. Neurohospitalist 2011; 1: 178-181
    PubMedGoogle Scholar
  • 56 Blanc F, Ruppert E, Kleitz C et al. Acute limbic encephalitis and glutamic acid decarboxylase antibodies: a reality?. J Neurol Sci 2009; 287: 69-71
    CrossrefPubMedGoogle Scholar
  • 57 Frisch C, Malter MP, Elger CE et al. Neuropsychological course of voltage-gated potassium channel and glutamic acid decarboxylase antibody related limbic encephalitis. Eur J Neurol 2013; 20: 1297-1304
    CrossrefPubMedGoogle Scholar
  • 58 Irani SR, Pettingill P, Kleopa KA et al. Morvan syndrome: clinical and serological observations in 29 cases. Ann Neurol 2012; 72: 241-255
    CrossrefPubMedGoogle Scholar
  • 59 Sunwoo JS, Lee ST, Byun JI et al. Clinical manifestations of patients with CASPR2 antibodies. J Neuroimmunol 2015; 281: 17-22
    CrossrefPubMedGoogle Scholar
  • 60 Lancaster E, Huijbers MG, Bar V et al. Investigations of caspr2, an autoantigen of encephalitis and neuromyotonia. Ann Neurol 2011; 69: 303-311
    CrossrefPubMedGoogle Scholar
  • 61 Lai M, Hughes EG, Peng X et al. AMPA receptor antibodies in limbic encephalitis alter synaptic receptor location. Ann Neurol 2009; 65: 424-434
    CrossrefPubMedGoogle Scholar
  • 62 Graus F, Boronat A, Xifro X et al. The expanding clinical profile of anti-AMPA receptor encephalitis. Neurology 2010; 74: 857-859
    CrossrefPubMedGoogle Scholar
  • 63 Hoftberger R, van Sonderen A, Leypoldt F et al. Encephalitis and AMPA receptor antibodies: Novel findings in a case series of 22 patients. Neurology 2015; 84: 2403-2412
    CrossrefPubMedGoogle Scholar
  • 64 Lancaster E, Lai M, Peng X et al. Antibodies to the GABA (B) receptor in limbic encephalitis with seizures: case series and characterisation of the antigen. Lancet Neurol 2010; 9: 67-76
    CrossrefPubMedGoogle Scholar
  • 65 Carvajal-Gonzalez A, Leite MI, Waters P et al. Glycine receptor antibodies in PERM and related syndromes: characteristics, clinical features and outcomes. Brain 2014; 137: 2178-2192
    CrossrefPubMedGoogle Scholar
  • 66 McKeon A, Martinez-Hernandez E, Lancaster E et al. Glycine receptor autoimmune spectrum with stiff-man syndrome phenotype. JAMA Neurol 2013; 70: 44-50
    CrossrefPubMedGoogle Scholar
  • 67 Tobin WO, Lennon VA, Komorowski L et al. DPPX potassium channel antibody: frequency, clinical accompaniments, and outcomes in 20 patients. Neurology 2014; 83: 1797-1803
    CrossrefPubMedGoogle Scholar
  • 68 Lancaster E, Martinez-Hernandez E, Titulaer MJ et al. Antibodies to metabotropic glutamate receptor 5 in the Ophelia syndrome. Neurology 2011; 77: 1698-1701
    CrossrefPubMedGoogle Scholar
  • 69 Sabater L, Gaig C, Gelpi E et al. A novel non-rapid-eye movement and rapid-eye-movement parasomnia with sleep breathing disorder associated with antibodies to IgLON5: a case series, characterisation of the antigen, and post-mortem study. Lancet Neurol 2014; 13: 575-586
    CrossrefPubMedGoogle Scholar
  • 70 Malter MP, Elger CE, Surges R. Diagnostic value of CSF findings in antibody-associated limbic and anti-NMDAR-encephalitis. Seizure 2013; 22: 136-140
    CrossrefPubMedGoogle Scholar
  • 71 von Rhein B, Wagner J, Widman G et al. Suspected antibody negative autoimmune limbic encephalitis: outcome of immunotherapy. Acta Neurol Scand 2016; DOI: 10.1111/ane.12575. [Epub ahead of print]
    PubMedGoogle Scholar